Vitamin D deficiency affects more than 1 billion people worldwide. Thirty to fifty percent of the U.S population has insufficient levels of vitamin D. Well-known for its major contribution to bone health, vitamin D has attracted the attention of science for its restorative role in cardiovascular diseases and cardiac injury, especially in chronic kidney disease (CKD) patients. Over the past few decades, research on vitamin D and its role in cardiovascular disease has been rapidly expanding, and now the direct association of vitamin D signaling and cardiovascular dysfunction and disease has been clearly recognized. Although a clear mechanism of how the restoration of vitamin D levels benefits cardiovascular health has yet to be identified, a number of clinical studies on vitamin D supplementation have shown its promise as a novel cure for cardiovascular diseases.
Introduction
Since the discovery of its role in curing rickets, vitamin D has been extensively studied by many researchers from a range of fields. Initially, it was mainly known for its crucial role in mineral metabolism and bone health. The population affected by vitamin D deficiency and insufficiency is estimated at more than 1 billion worldwide (Holick 2007) . Also, between 30% and 50% of the U.S. population have inadequate levels of vitamin D and 8% are at risk of vitamin D deficiency (Looker et al. 2011) . Beyond its chief role in bone health, vitamin D has drawn much attention for its effects in chronic kidney disease (CKD) patients and its association with cardiovascular risks. Patients with CKD are known to be strongly vitamin D deficient due to impaired 1α-hydroxylase enzyme activity in the kidney (Quarles 2008). In the same context, vitamin D levels are closely related to the risk of mortality and survival rates for endstage renal disease patients. According to many observational cohort studies, 78% of hemodialysis patients are vitamin D deficient, and the 2-year mortality rate is more than doubled for patients who were not treated with injectable vitamin D therapy compared to treated patients (Teng et al. 2005 ; Wolf et al. 2007 ). Also, it is estimated that the rate of cardiac failure among patients undergoing hemodialysis is almost 40%, and that vitamin D deficiency is an independent indicator of early death in CKD patients (Foley et al. 1998 ; Gonzalez et al. 2004 ). Above all, growing evidence strongly suggests that vitamin D is associated with cardiovascular diseases such as congestive heart failure, thereby suggesting a clinically beneficial role in the treatment of these diseases. In this review, we investigate the relationship between vitamin D and cardiovascular risk factors, as well as potential preventive and restorative effects of vitamin D therapy on the initiation and progression of cardiovascular events.
Metabolism and function of vitamin D
Vitamin D is predominantly synthesized in the skin by the photochemical conversion of 7-dehydrocholesterol into vitamin D3 (cholecalciferol). This precursor compound exerts no significant biological effects. It is later hydroxylated in the liver to form 25-dihydroxyvitamin D3, which is a long-lived circulating storage form of the vitamin (Okano et al. 1977) . It is further hydroxylated in the kidneys to form 1,25-dihydroxyvitamin D3, also known as calcitriol, which is the hormonally active form. This conversion is biologically critical, because calcitriol is the mediator of almost all biological pathways targeted by vitamin D. It exerts its effects on tissues by binding the nuclear membrane vitamin D receptor (VDR). Upon biding, VDR translocates to the nucleus and forms a heterodimer with members of retinoid X receptor (RXR) family of receptors (Jones et al. 1998 al. 2008) . Recently, it was demonstrated that treatment with paricalcitol effectively prevents pre-existing cardiac hypertrophy from becoming further aggravated and developing into heart failure in rats fed with high-salt diet. This particular study presented remarkable evidence that PKC-α activation in the heart is attenuated by paricalcitol treatment, thus possibly pointing to an important mechanism that regulates cardiac function (Bae et al. 2011). Another study that examined doxercalciferol, or 1α-hydroxyvitamin D2 (vitamin D2 pro-hormone) has substantiated this association. The study found that administration of doxercalciferol reduced cardiac hypertrophy due to a high-salt diet in rats (Choi et al. 2011). VDR activation also improves diastolic function, as it alters calcium flux and consequently encourages the relaxation of cardiomyocytes (Green et al. 2006 ). Moreover, it has been found that VDR has direct anti-hypertrophic activity on cardiomyocytes, apart from the suppressed renin effect (Chen and Gardner 2012). Overall, the direct association of vitamin D signaling and cardiovascular dysfunction and disease has been clearly recognized, and vitamin D therapy thus promises to be novel approach that might complement currently available therapies for heart failure.
Clinical and epidemiological studies
Numerous clinical and epidemiological studies have suggested a strong association between vitamin D deficiency and cardiovascular disease in the general population. The results found that vitamin D levels are highly associated with the incidence of arterial disease, myocardial infarction, heart failure, stroke, and other cardiovascular diseases (Wang et al. 2008; Anderson et al. 2010 ).
According to data from the NHANES III (National Health and Nutrition Examination Survey), the Ui Kyoung Kim and Soochan Bae odds of having increased blood pressure is twice as great in adolescents with the lowest serum 25-hydroxyvitamin D levels (less than 15ng/ mL) than in groups of adolescents with higher levels (Thacher and Clarke 2011 Moreover, it appears that secondary hyperparathyroidism is associated with increased risk of cardiovascular events, such as elevated arterial pressure and myocardial contractility (Zittermann 2006) A recent epidemiological study conducted over a 29-year period found that stepwise increases in the risk of ischemic heart disease, myocardial infarction (MI) and early death occur with stepwise decreases of plasma 25-hydroxyvitamin D levels. Those with the lowest levels of vitamin D had a 40% increased risk of ischemic heart disease, a 64% higher chance of an MI, a 57% increased risk of early death, and an 81% higher likelihood of fatal ischemic heart disease/MI (BrondumJacobsen et al. 2012). Another interesting study to note is the MONICA/KORA Augsburg casecohort study, which examined the cases of coronary disease in healthy middle-aged men and women over a follow-up period of 11 years. The results captured a novel gender-specific relationship between higher vitamin D serum levels and decreased coronary disease cases: that vitamin D level was more strongly associated with cardiovascular risks in women than men. 
Renin-Angiotensin System
The renin-angiotensin system (RAS) regulates blood pressure, intravascular volume, and electrolyte homeostasis via renin released from juxtaglomerular cells. It promotes the conversion of angiotensinogen to angiotensin I, which is then converted to angiotensin II by angiotensin converting enzyme (ACE). Vitamin D has a function as a negative regulator of the RAS by 
Inflammation
Recently, vitamin D has attracted much attention, as it has been suggested to play a critical regulatory role in inflammation, which is one of the factors leading to cardiovascular risks. A low 25-hydroxyvitamin D level increases the levels of C-reactive protein and IL-10, thus leading to a higher risk of inflammation (Zittermann 2006 ). This association has been further supported by the finding that vitamin D supplementation promotes the serum concentration of anti-inflammatory cytokine IL-10, and suppresses the increase in serum levels of the pro-inflammatory cytokine TNF-α in congestive heart failure patients. These results suggest downregulatory effects of vitamin Furthermore, there has been building evidence pointing to omega-3 fatty acids as a potential means of treatment for cardiovascular events. In the GISSI-P study launched in 2004, daily supplementation with omega-3 fatty acids, in addition to regular medical treatment, had the effect of reducing cardiac and all-cause mortality for post-myocardial infarction patients (Guttler et al. 2012) Likewise, there has been an ongoing trial, called VITAL, which involves vitamin D and omega-3 fatty acids and their efficacy in the primary prevention of cardiovascular diseases and cancer. Although no affirming clinical evidence is yet available, the role omega-3 fatty acids in cardiovascular diseases is another area of interest from which the vitamin D research field could find inspiration for future research.
Conclusion
Extensive evidence collected over the past decade clearly suggests a strong association between low serum vitamin D levels and the risk of cardiovascular diseases and dysfunctions. Also, several potential mechanisms whereby vitamin D may affect the pathophysiology of cardiovascular disease events have been recognized, through many laboratory studies in animal models and at a molecular level. However, a clear mechanism as to how vitamin D restoration benefits cardiac health and restores heart function has yet to be clearly identified. Currently, insufficient interventional data from randomized controlled trials (RCT) is available make any conclusions on the effects of vitamin D intake on cardiovascular disease, especially in humans. To further solidify the relationship between vitamin D and cardiovascular risk factors, more RCTs with larger groups are still needed to determine whether vitamin D therapy will alleviate clinically meaningful cardiovascular events such as myocardial infarction, heart failure and hypertrophy. 
